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Left or biventricular (BiV) pacing, or cardiac resynchronization therapy, was proposed nearly
10 years ago as an adjunctive treatment for patients with advanced heart failure (HF)
complicated by discoordinate contraction due to intraventricular conduction delay. Since
then, both short-term and a growing number of long-term clinical trials have reported on the
mechanisms and short- and mid-term efficacy of this approach, with encouraging results.
Therapy is implemented with novel pacing systems incorporating an endocardial lead to
stimulate the lateral free wall via a cardiac vein, and often a right ventricular (RV) apex lead
to provide BiV stimulation. A third atrial sensing lead monitors intrinsic rhythm and provides
timing data to ensure ventricular pre-excitation. Modulation of the electronic atrial-
ventricular (AV) time delay can optimize contractile synchrony, enhance the contribution of
atrial systole, and reduce mitral regurgitation. Individuals with advanced HF, a wide QRS
complex often with an AV time delay, and evidence of contraction dyssynchrony in viable
myocardium represent the target patient group. Short-term studies reveal systolic augmen-
tation and chamber efficiency from pacing resynchronization that can be substantial.
Long-term studies reveal improved symptoms and exercise capacity, and some report reversal
of chronic cardiac dilation. However, important questions regarding long-term efficacy and
mortality impact, optimal mode for pacing stimulation, and role of combined pacing/
cardioverter/defibrillation devices remain unresolved. Here we review pathophysiologic
mechanisms, short- and long-term clinical results, and future directions of this new and
promising therapy. (J Am Coll Cardiol 2002;39:194–201) © 2002 by the American
College of Cardiology
Over the past two decades, the focus of heart failure (HF)
pathophysiology and treatment has shifted from abnormal-
ities of chamber function and hemodynamics to changes
affecting the myocardium itself. Current therapies target
neurohormonal cascades and stress response signaling cou-
pled to chamber remodeling, dilation, and progressive
deterioration (1–5). Whereas many abnormalities are best
understood at the myocardial level, key features remain
determined by the integrated chamber. A prime example is
the influence of electrical activation on the timing of atrial
and ventricular systole and synchronous contraction of the
muscle wall. Recent studies have revealed that intraventric-
ular conduction block with or without prolonged atrial-
ventricular (AV) delay adversely influences ventricular func-
tion due to discoordinate contraction (6–13). This is usually
indicated on the surface electrocardiogram by widening of
the QRS complex, a finding associated with increased
morbidity and mortality in HF patients (14–16).
Both contractile discoordination and abnormal AV tim-
ing can be offset by non-conventional pacing stimulation in
which leads are placed on the left ventricular (LV) free-wall
or in a biventricular (BiV) configuration (second lead in the
right ventricle [RV]) and pre-excitation is employed to
restore physiologic AV timing (17–19) and contraction
synchrony (10,20–28). This therapy is increasingly being
termed cardiac resynchronization, and over the past year
alone, more than 20 studies have reported short- or long-
term effects from the treatment, including recent studies
with placebo controls. Based on the results, the Food and
Drug Administration (FDA) recently approved the therapy
for the treatment of moderate-to-severe HF in patients
refractory to drug treatment who have contractile dyssyn-
chrony due to conduction delay. This approval comes as
larger multicenter trials continue with the important goal of
assessing the impact of resynchronization therapy on mor-
tality. In this review, we have aimed to summarize the
underlying pathophysiologic mechanisms, clinical status,
and future directions of this rapidly emerging and novel
approach to HF treatment.
PATHOPHYSIOLOGY OF ABNORMAL
ELECTRICAL TIMING: DYSSYNCHRONY AND AV DELAY
The two primary targets of resynchronization therapy are
the pattern of LV activation, and the delay between atrial
and ventricular systole. The LV normally contracts synchro-
nously with little more than 40 ms variation in the onset of
electrical activation throughout the wall and very similar
low-level variability in the timing of mechanical activation
as well. Synchrony of contraction is important because it
results in more effective and energetically efficient ejection.
When a portion of the heart is prematurely stimulated, as
for example with a left bundle branch block (LBBB) or
single-site ventricular pacing, the activation sequence
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changes markedly, generating regions of both early and
delayed contraction (29–31). Early shortening at the stim-
ulation site is wasted work because pressure is still low and
no ejection is occurring. Late activation of the region remote
to the stimulator occurs at higher stress because the paced
territory has already developed tension, yet it is also char-
acterized by wasted work because the early activated terri-
tory may now undergo paradoxical stretch (32). The net
result is a decline in systolic function of about 20% with
reduced cardiac output and increased end-systolic volume
and wall stress (33,34), delayed relaxation (35,36), and
decline in efficiency (37,38). The mechanical dysfunction
arising from delayed intrinsic conduction delay (e.g.,
LBBB) versus single-site pacing (e.g., RV apex) is not
necessarily equivalent. Rather, the data suggest the former
has worse effects on contraction as a larger territory of
myocardium is prematurely activated (39). Discoordination
may also contribute to abnormal regional function and
pro-arrhythmia (40,41). Late-systolic stretch of the myo-
cardium, which is observed in the discoordinate septum
(27,32), can lower force generation by rapidly disrupting
cross-bridges. In addition, such mechanical stretch can
trigger calcium release to induce after-contractions and
arrhythmia (40,41).
In addition to intraventricular conduction, the AV time
delay also influences net chamber mechanics—with too
short or too long an interval resulting in sub-optimal
chamber filling and contributing to mitral regurgitation
(MR) (17). The latter occurs as the mitral valve re-attains an
open midstream configuration during late diastole (after
atrial contraction), which promotes regurgitation during the
onset of ventricular systole (42). Experimental data in
normal animals first showed a 15% decline in optimal
cardiac output at either extreme of AV timing (43). How-
ever, translation of this behavior to the failing heart is
non-trivial because such hearts often operate at high filling
pressures, which reduces the volume contribution of atrial
systole—even if optimally timed. In this situation, varying
AV delay is less likely to affect net cardiac filling. Nonethe-
less, some studies have found linkage between optimal
timing of atrial systole relative to the onset of ventricular
activation and improved cardiac ejection in HF patients
(44), and AV delay can have potent influences on the
available diastolic filling time and pre-systolic MR (17).
Finally, MR can also complicate atrial fibrillation owing to
irregular cycle lengths and thus sub-optimal valve position-
ing, and this might be offset by rate regularization via AV
node ablation followed by synchronous stimulation.
ACUTE CLINICAL STUDIES: MECHANISMS
Initial clinical studies of pacing/stimulation therapy in HF
patients focused on the effects of shortening AV delay.
Small-scale trials indicated hemodynamic benefit for pa-
tients with a very long PR interval (often exceeding 300 ms)
with pre-systolic MR and compromised diastolic filing time
(17). However, this initial encouragement was not sup-
ported by subsequent studies (45). One potential factor was
that in patients with an otherwise normal electrical activa-
tion sequence (narrow QRS complex), RV apical pacing
generated de novo discoordination, thereby worsening func-
tion. Furthermore, in those patients who had dyssynchro-
nous contraction with left free wall contraction delay, RV
pacing did not correct the timing abnormality. High out-
flow tract pacing was also attempted, but the results were
also generally disappointing (46). By the mid-1990s, the
target changed from optimizing the AV delay to placing
stimulation leads in those locations most likely to restore
contractile synchrony.
Table 1 summarizes the recent clinical studies investigat-
ing the acute efficacy and mechanisms for biventricular
(BiV) (and/or left ventricle [LV] only) stimulation effects.
After the first report in 1983 involving four patients (47), it
was nearly 13 years before the first systematic analysis was
presented (21). Since then, BiV pacing has been shown to
markedly improve cardiac output, increase systolic pressure,
lower pulmonary wedge pressure (22,23), enhance ventric-
ular systolic function as assessed by maximal rate of pressure
rise (25,26) and pressure-volume loops (26), and improve
the magnitude and synchrony of wall contraction (48,49).
Furthermore, both BiV and LV-only pacing can generate
systolic improvement while concomitantly reducing myo-
cardial energy consumption, resulting in improved chamber
efficiency (28). Short-term BiV pacing also reduces sympa-
thetic activity, probably because of enhanced systolic func-
tion (50). For the majority of these studies, stimulation has
been achieved with a dual-chamber pacing system in which
the atrial lead senses activation and ventricular lead(s)
prematurely excite the heart by means of a shortened AV
delay. The target patients generally had severe HF (New
York Heart Association [NYHA] functional class III–IV)
with rest ejection fractions 20%, and most had a left
bundle-branch conduction defect with QRS durations of
150 ms or more.
These short-term studies also revealed at least three
unexpected and intriguing findings. One was that the
immediate effects of single-site LV activation were often
similar or even more prominent that those from BiV
stimulation (23,25,26). To date, the latter has involved
simultaneous stimulation of RVs and LVs, and this is not
necessarily optimal, particularly in dilated failing hearts.
Abbreviations and Acronyms
AV  atrial-ventricular
BiV  biventricular
HF  heart failure
ICD  implantable cardioverter-defibrillator
LV  left ventricle/left ventricular
MR  mitral regurgitation
NYHA  New York Heart Association
RV  right ventricle/right ventricular
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Although LV pacing alone pre-excites the lateral wall and
thus might seem to simply shift electrical delay to the right
side, the mechanical effects appear different. This may relate
to the requirement for intramyocardial spread of electrical
conduction from the LV pacing site, versus intra-fasicular
conduction in the preserved right bundle. In addition, BiV
pacing has thus far been studied with synchronous stimu-
lation of both ventricles. This does not recapitulate normal
activation and may be suboptimal. Second, whereas modi-
fying AV delay influenced the net systolic response to LV or
BiV pacing, this was a more modest effect compared with
the pacing site itself. Over a broad range of delays (PR
interval from 110 to 140 ms), the mechanical responses to
BiV and LV-only pacing appear similar (25,26), and both
are greater than with RV pacing. Finally, studies have not
revealed short-term benefits (or detriments) on cardiac
diastolic function as indexed directly by the isovolumic
relaxation time constant and the diastolic pressure-volume
curve (26).
Identifying patients likely to respond. A central issue for
resynchronization therapy is the identification of candidates
most likely to benefit. The primary variable has been QRS
duration—an electrical marker for spatially dispersed me-
chanical activation. Experimental studies have shown that
the greater the degree of pacing-induced LV discoordina-
tion and dysfunction, the wider the associated electrical
complex (33), and patients with wider QRS complexes have
a greater immediate mechanical response to resynchroniza-
tion therapy (25–27,51,52). Additionally, the worse the
cardiodepression, perhaps itself reflecting dyssynchrony, the
greater the resynchronization response (27). This dysfunc-
tion may be indexed by ejection fraction (22), basal dP/dtmax
(27), Doppler echocardiographic indexes of diastolic-to-
cycle-length ratio (53), or Doppler measures of isovolumic
contraction. Direct analysis of dyssynchrony may also be
feasible by means of magnetic resonance imaging (27),
tissue Doppler strain analysis (54), or contrast echocardiog-
raphy (55). Such measures appear to provide the strongest
correlate with responsiveness to resynchronization (27).
One aspect that has been somewhat controversial is whether
QRS narrowing with BiV or LV stimulation can be used to
indicate treatment efficacy. Short-term studies have not
found this correlation, which is probably related to the
intramyocardial conduction that exists with pacing regard-
less of the more global synchrony that may be produced.
However, some long-term studies have suggested that a
narrower QRS correlates with better long-term efficacy (56),
and these issues remain to be reconciled.
Simple mechanical measures might also be employed to
examine the efficacy of resynchronization therapy—such as
artery pulse pressure or cardiac output. Preliminary data
suggests that short-term enhancement of some parameters
correlates with long-term improvement; this relationship is
being clarified by several ongoing studies. It might be useful
to measure a mechanical response when placing the lead to
improve pacing-site selection, although this has rarely been
done thus far.
CHRONIC CLINICAL STUDIES
There are now a half-dozen completed clinical studies
involving long-term multisite (BiV) cardiac stimulation for
the treatment of advanced dilated cardiomyopathy with
underlying conduction delay (QRS  120 to 150 ms).
These studies are summarized in Table 2. Early experience
began in Europe with the work of Bakker et al. (57), Cazeau
Table 1. Short-Term Studies With Temporary LV or BiV Paving in Patients With Intraventricular Conduction Delay
Reference
Study
Date
No. of
Patients
Pacing Modes
Compared Primary Output Results vs. Baseline or AAI
De Teresa (47) 1983 4 no pacing/LV radionuclide imaging LVEF: 25% in LV
Cazeau (21) 1996 8 no pacing/RV/BiV hemodynamics CI: 28% in BiV / PCWP: 16% in BiV
Blanc (23) 1997 23 no pacing/BiV/LV hemodynamics SBP: 7% / PCWP: 22%/V wave:
30% in BiV and LV
Leclercq (22) 1998 18 AAI/RV/BiV hemodynamics CI: 35% / PCWP: 18%/V wave: 21% in BiV
Saxon (48) 1998 11 no pacing/RV/LV/BiV echocardiography fractional area change: 19% in BiV
Kass (26) 1999 18 no pacing/RV/LV/BiV hemodynamics dP/dt 23% / PP: 18% in LV
dP/dt 13% / PP: 15% in BiV
LV  BiV
Auricchio (25) 1999 27 no pacing/RV/LV/BiV hemodynamics dP/dt 15% / PP: 7.5% in LV
dP/dt 14% / PP: 6.5% in BiV
LV  BiV
Nelson (27) 2000 22 no pacing/LV hemodynamics dP/dt 35% / PP: 16% in LV
MRI imaging predictive  factors: QRS 155 ms  dP/dt
700 mm Hg/s
Nelson (28) 2000 10 no pacing/LV hemodynamics dP/dt 43% / PP: 19% in LV
ENERGETICS AVo2: 4% / MVo2: 6% in LV
Kerwin (49) 2000 13 no pacing/BiV radionuclide LVEF: 29% / IVS 48% in BiV
Hamdan (50) 2000 13 RV/LV/BiV SNA neurography SNA: 11% in LV/15% in BiV
AVo2  arterial-coronary sinus oxygen difference; BiV  biventricular; CI  cardiac index; CO  cardiac output; IVS  interventricular synchrony; LV  left ventricular;
LVEF left ventricular ejection fraction; MVo2 myocardial oxygen consumption; PCWP  pulmonary capillary wedge pressure; PP  pulse pressure; SBP  systolic arterial
pressure; SNA  sympathetic nerve activity; SVR  systemic vascular resistance.
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et al. (21), and others (58). To date, three placebo control
studies have been completed: the PATH-CHF trial (59),
the MUSTIC trial (60), and the MIRACLE trial (61,62).
In the PATH-CHF study, patients were first assigned to
four weeks of active pacing (LV or BiV), then four weeks of
no pacing, then a second four-week active pacing period—
continued for the ensuing year. This was a single-blind
study and required surgically implanted leads and two
stimulators. Importantly, exercise performance (e.g., maxi-
mal oxygen consumption) rose significantly only during the
two periods of active pacing. This finding in the third
month (after a month of no-pacing) was somewhat more
difficult to ascribe to a placebo effect.
The recently published MUSTIC study (60) used a
cross-over design, with patients randomized to three
months’ stimulation on or off and the mode then switched
for the second three-month period. In sinus rhythm pa-
tients, exercise capacity improved only during active treat-
ment (23% in 6-min walking distance, p  0.001),
improved symptoms (32% in quality-of-life questionnaire,
p  0.001) and increased maximal oxygen consumption
(8%, p  0.03). Interestingly, this study did not observe a
placebo effect. A separate component of this study evaluated
patients with chronic atrial fibrillation, each patient under-
going AV nodal ablation prior to receiving a BiV stimula-
tion system (63). Intention-to-treat analysis failed to reveal
significant differences between pacing on and off data,
although limitations due to study design and loss of effective
pacing in several subjects contributed to this. In the subset
of subjects in which pacing was effectively delivered, the
results suggested improvement, but this needs more defin-
itive testing.
The recently completed MIRACLE trial is the largest
study to date. Preliminary data have been reported (61,62),
and a full publication is pending. This six-month parallel-
design trial randomized 228 patients to resynchronization
therapy and another 225 patients to a placebo control arm.
All patients were in normal sinus rhythm and were stable
NYHA functional class III or class IV. The primary
findings showed an improvement in the 6-min walk test,
quality-of-life score, and NYHA functional class (a com-
bined end point was also examined). Secondary end points
were also assessed in a subset of patients, and the data
support a diminished diastolic and systolic chamber size in
the active resynchronization treatment but not in the
placebo group. Mortality was10% in both treatment arms
at six months. Rehospitalization rates and number of days
hospitalized were both significantly and substantially lower
in the active treatment group. The investigators reported a
placebo effect with respect to quality of life but not for
exercise or cardiac-function parameters.
In addition to these main trials, several smaller studies
have reported improved quality of life (64), reduced hospi-
talization (65), and antiarrhythmic activity (66,67) from
resynchronization therapy. The level of enhanced exercise
capacity is nontrivial, and it compares favorably with thatTa
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reported with angiotensin-converting enzyme inhibitors
and beta-blockers (68,69). Long-term follow-up data from
these trials have not yet been published, although prelimi-
nary results have been presented at recent national meetings.
For the MUSTIC trial, functional benefit was sustained
during the one-year follow-up period; for the PATH-CHF
study, two- and three-year mortality rates have been re-
ported at 86% and 75%, respectively (70).
Additional trials are currently underway in the US and
Europe to address important unanswered issues (Table 3).
Several studies are evaluating the efficacy of combining
internal defibrillation with BiV resynchronization (MIRA-
CLE ICD, CONTAK CD, INSYNC ICD, BELIEVE).
Data from one such study reported that implantable
cardioverter-defibrillator (ICD) firings were significantly
less frequent during the randomized period when resyn-
chronization therapy was applied (66,67), although this has
not yet been confirmed in larger trials. Other studies are
addressing whether resynchronization therapy improves
mortality (COMPANION, CARE-HF, PACMAN). The
COMPANION study is the largest, with a target recruit-
ment of 2,200 patients (71), and it is powered to determine
a mortality benefit of 25% in patients with dilated cardio-
myopathy and a basal QRS duration 120 ms. It includes
a placebo group, a combined ICD and resynchronization
therapy group, and a group receiving resynchronization
therapy only. Finally, studies are planned to test the relative
merits of single-site LV pacing versus BiV pacing for
resynchronization (BELIEVE, PAVE and OPTSITE).
Preliminary data from the PATH-CHF 1 study have not
found significant differences between these modes.
IMPLEMENTATION: NEW TECHNOLOGIES
As of April 2001, more than 1,000 individuals involved in
various trials have received some form of resynchronization
pacing therapy. The vast majority of these patients received
an endocardially placed coronary venous lead system (72).
This application has required the development of novel
leads that can better reach the target site (often lateral
cardiac wall), maintain lead stability after placement, and
provide acceptable pacing thresholds.
The question of precisely where on the LV optimal
pacing is achieved remains incompletely resolved and is
likely to vary somewhat from patient to patient. Butter et al.
(73) reported that short-term systolic response did depend
on the LV pacing site, with the mid-part of the LV lateral
wall generally providing the greatest improvement in most
patients (73). One potential explanation is that pre-
excitation of the left lateral wall optimally offsets the region
with the greatest basal delay in activation and may also help
ameliorate MR by pre-stimulating the papillary muscle.
Multiple LV sites may be even better than a single site (74),
but this remains to be more fully studied.
Initial lead placement was surgical, and although surgical
mortality was low (Auricchio A, personal communication,
2001), the approach was largely abandoned owing to atten-
dant morbidity from the surgery itself. A transvenous
approach was introduced by Daubert et al. in 1998 (75), and
this approach has since become the mainstream method,
employing specifically designed leads to assist in placement.
With these improvements, implantation success has risen
from 50% to 85% or higher (76,77). The target location
Table 3. Ongoing Trials With Multisite Cardiac Pacing
Inclusion Objectives Randomized
Primary
End Point
COMPANION Class III/IV; LVEF  35% no pacing vs. BiV vs.
BiV  ICD
yes Death/All hosp
QRS  140 ms follow-up: 2 years
CARE-HF Class III/IV; LVEF  35% no pacing vs. BiV vs.
BiV  ICD
yes Death/CV hosp
QRS  150 ms or follow-up: 1.5 years
QRS  120 ms  dyssynchrony
Echocardiography criteria
PACMAN Class III; LVEF  35% no pacing vs. BiV 
ICD if indicated
yes 6 WT
QRS  150 ms cross-over 6 months
PATH-CHF 2 Class II–IV; LVEF  35% optimized pacing vs. no
pacing  ICD if indicated
yes 6 WT and CPX
QRS  120 ms cross-over 6 months
Ventak Class II–IV; LVEF  35% no pacing  ICD vs.
BiV  ICD
yes CPX
QRS  120 ms cross-over 3 months
VECTOR Class II–IV; LVEF  35% no pacing vs. BiV yes 6 WT and QOL
QRS  140 ms cross-over 6 months
PAVE AV node ablation/chronic AF RV vs. LV vs. BiV yes/3 arms/6 months’ follow-up 6 WT and QOL
BELIEVE Class II–IV; LVEF  35% LV  ICD vs. BiV  ICD yes/1-year follow-up Echocardiography
QRS  130 ms  ICD indication
INSYNC III Class III–IV; LVEF  35% safety/efficacy new device no/6 months’ follow-up 6 WT and QOL
QRS  130 ms  ICD indication
MIRACLE ICD Class II–IV; LVEF  35% no pacing  ICD vs.
BiV  ICD
yes 6 WT and QOL
QRS  130 ms  ICD indication cross-over 6 months
OPTSITE AV node ablation/chronic AF RV vs. LV vs. BiV yes/3 arms/6 months’ follow-up 6 WT and QOL
AF  atrial fibrillation; AV  atrioventricular; BiV  biventricular; CPX  cardiopulmonary exercise; hosp  hospitalization; ICD  implantable cardioverter-defibrillator;
LVEF  left ventricular ejection fraction; QOL  quality of life; 6 WT  6-min walking test.
198 Leclercq and Kass JACC Vol. 39, No. 2, 2002
Retiming the Failing Heart January 16, 2002:194–201
(i.e., a lateral or posterolateral vein in mid-cavity position)
can be reached in a majority of patients (about 75%), and
similar results have been reported by several groups using
various technologies (78,79).
Implantation of an LV lead via the coronary sinus poses
some technical challenges, most often related to a dilated
right heart anatomy and/or variable or suboptimal coronary
venous anatomy. Both can render coronary sinus cannula-
tion and lead placement more difficult. Although overall
reported complication rates have been generally low, one
must keep in mind that most of these data have come from
centers with extensive experience, and there is a well-
recognized and important learning curve involved with
implantation. Furthermore, HF patients ill-tolerate compli-
cations related to arrhythmia or perforation, so care and
caution are always indicated. The major serious complica-
tions are dissections or perforations of the coronary sinus (or
cardiac vein), which result in cardiac tamponade. In the
series by Ricci et al. (78), the latter complication occurred in
0.9% of 190 patients treated. In the Rennes Hospital
experience, the rate of coronary sinus dissection was 2% (out
of 102 patients), but none of these instances led to further
adverse clinical consequences. Pacing thresholds in the
1–1.5-V range are achieved in approximately 90% of sub-
jects, and many maintain such thresholds over the long
term. Further improvements in lead technology and in the
coronary sinus introducer sheaths should improve on these
statistics. Steerable sheaths, which assist in negotiating the
dilated right heart anatomy that often complicates coronary
sinus cannulation, may also improve success rates. Several
alternative approaches such as a transseptal (80) or
pericardial-epicardial approach may be useful in cases with
coronary sinus or venous anatomy failure. The surgical
epicardial approach may still be considered useful in appro-
priate candidates for whom heart surgery is already indi-
cated, or for those with failed transvenous lead implantation
due to anatomic or technical difficulties.
Although data on short-term pacing effects of BiV versus
LV stimulation show equivalence or slight superiority to LV
pacing, BiV pacing remains the dominant method under
clinical study. In this regard, the optimal placement of the
right heart lead is itself somewhat controversial. For most
trials, this lead is placed at the RV apex. However, alterna-
tive locations, such as the mid-upper RV septum, are feasible
and may or may not provide additional improvement. This
potentially important question needs to be resolved.
Initial studies employed a Y-adaptor and existing DDDR
pacing systems to link both ventricular leads to the single
ventricle outport. This resulted in a substantial number of
technical failures, but current generator systems with three
dedicated ports have largely resolved this problem. How-
ever, only recently has the output to both ventricles been
truly independent. Most existing and ongoing studies in-
volve systems tying both leads to a common internal current
source. This runs the risk of an impedance mismatch that
could result in only RV or only LV pacing, rather than both.
New devices have two independent channels and further
add programmability of the RV–LV stimulation delay.
These are under current investigation.
UNSOLVED ISSUES, FUTURE DIRECTIONS
Although much has been learned over the past several years
regarding resynchronization therapy, many important ques-
tions remain unanswered. Clearly, there are major impor-
tant questions about whether there is a sustained benefit on
morbidity and reduced hospitalization and whether there is
a favorable effect on overall and cardiac mortality. In this
regard, it is important that the ongoing trials such as
COMPANION, which are addressing these key questions,
proceed to completion so that the role of this therapy can be
properly and fully evaluated. The mortality impact of
resynchronization may ultimately be tied in with ICDs,
particularly if the results of ongoing multicenter trials show
survival benefits from such devices in HF.
Another question relates to the prospective identification
of responders. New methods examining regional wall mo-
tion hold promise for generating a dyssynchrony index that
could improve on current, more indirect methods. The optimal
method of therapy itself is unresolved. As noted, questions
remain as to whether BiV stimulation is needed, whether
multisite left-heart stimulation would enhance the efficacy, or,
if an RV lead is to be placed, where the optimal location is and
what the best timing delay is between RV and LV stimulation.
A large unresolved question is whether this therapy is
going to be useful in patients with atrial fibrillation. Some
studies have suggested utility (81), although larger trial data
remain inconclusive (64). Unlike the sinus rhythm patients,
in which there is some degree of freedom in the AV delay
to optimally time a resynchronization effect, the AV node in
atrial fibrillation patients is generally ablated, and then
patients are treated using a BiV pacing mode. This involves
regularization of the heart rate with rate-responsive gener-
ators, as well as activation of both lower chambers. Rate
response serves to simulate normal effects of autonomic
tone, but it is not a perfect replacement for physiologic
control. Furthermore, in patients without an existing con-
duction delay, BiV pacing may not yield as good a response
as that with His-Purkinje conduction. More studies are
clearly needed in these patients.
Finally, the existing evidence indicating deterioration of
systolic function and energetic efficiency with pacing-
induced dyssynchrony suggests that standard RV apex
pacing in individuals with cardiac failure may not be the
ideal approach. In patients with cardiodepression but a
narrow QRS complex and normal intraventricular conduc-
tion who need pacing for rate control, a BiV system may
prove superior, but this clearly needs to be tested.
SUMMARY
Substantial data now support the hypothesis that LV or BiV
stimulation can improve cardiac function and efficiency in
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HF patients with discoordinate contraction due to abnormal
conduction. Several recent modest-sized placebo-controlled
trials suggest that the long-term benefits can be substantial
(60–62); and based on these data, this therapy recently
received FDA approval in selected HF patients. Its ultimate
utility and acceptance into HF management will depend on
fully establishing its indications and long-term therapeutic
value, refining the targeting of patients most likely to benefit
and enhancing the treatment delivery systems and technol-
ogies to achieve these goals. Much exciting work has already
been done, but there is much more still to do.
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